Indirect comparison showed survival benefit from adjuvant chemoradiotherapy in completely resected gastric cancer with D2 lymphadenectomy

Gastroenterology Research and Practice

Volumn 2013, Issue , 2013, Pages

  Yang, Qiong ^a   Wei, Ying ^a   Chen, Yan Xian ^a   Zhou, Si Wei ^b   Jiang, Zhi Min ^a   Xie, De Rong ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b HUIZHOU MUNICIPAL CENTRAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT CHEMORADIOTHERAPY; ADJUVANT CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; COHORT ANALYSIS; COMPARATIVE STUDY; DATA EXTRACTION; DISEASE FREE SURVIVAL; EMBASE; FOLLOW UP; HUMAN; LYMPH NODE DISSECTION; MEDLINE; META ANALYSIS; MULTIMODALITY CANCER THERAPY; OBSERVATIONAL STUDY; OVERALL SURVIVAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; STOMACH CANCER; SYSTEMATIC REVIEW;

EID: 84886686392     PISSN: 16876121     EISSN: 1687630X     Source Type: Journal    
DOI: 10.1155/2013/634929     Document Type: Review

References (25)

1. Jemal A., Bray F., Center M. M., Ferlay J., Ward E., Forman D., Global cancer statistics. CA Cancer Journal for Clinicians 2011 61 2 69 90 2-s2.0-79952232216 10.3322/caac.20107
2. Macdonald J. S., Role of post-operative chemoradiation in resected gastric cancer. Journal of Surgical Oncology 2005 90 3 166 170 2-s2.0-19644396607 10.1002/jso.20223 (Pubitemid 40741181)
3. Bouché O., Ychou M., Burtin P., Bedenne L., Ducreux M., Lebreton G., Baulieux J., Nordlinger B., Martin C., Seitz J. F., Tigaud J. M., Echinard E., Stremsdoerfer N., Milan C., Rougier P., Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). Annals of Oncology 2005 16 9 1488 1497 2-s2.0-24044444450 10.1093/annonc/mdi270 (Pubitemid 41226403)
4. Macdonald J. S., Smalley S. R., Benedetti J., Hundahl S. A., Estes N. C., Stemmermann G. N., Haller D. G., Ajani J. A., Gunderson L. L., Milburn Jessup J., Martenson J. A., Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. The New England Journal of Medicine 2001 345 10 725 730 2-s2.0-0035818048 10.1056/NEJMoa010187
5. Smalley S. R., Benedetti J. K., Haller D. G., Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. Journal of Clinical Oncology 2012 30 19 2327 2333
6. Leong C. N., Chung H. T., Lee K. M., Shakespeare T. P., Mukherjee R. K., Wong L. C., Lu J. J., Tey J., Lim R., So J. B. Y., Back M. F., Outcomes of adjuvant chemoradiotherapy after a radical gastrectomy and a D2 node dissection for gastric adenocarcinoma. Cancer Journal 2008 14 4 269 275 2-s2.0-57849098234 10.1097/PPO.0b013e318178d23a
7. Kim S., Lim D. H., Lee J., Kang W. K., MacDonald J. S., Park C. H., Park S. H., Lee S.-H., Kim K., Park J. O., Kim W. S., Jung C. W., Park Y. S., Im Y.-H., Sohn T. S., Noh J. H., Heo J. S., Kim Y. I., Park C. K., Park K., An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. International Journal of Radiation Oncology Biology Physics 2005 63 5 1279 1285 2-s2.0-27744437443 10.1016/j.ijrobp.2005.05.005 (Pubitemid 41628018)
8. Park S. H., Kim D. Y., Heo J. S., Lim D. H., Park C. K., Lee K. W., Choi S. H., Sohn T. S., Kim S., Noh J. H., Kim Y. I., Park J. O., Kim K., Kim W. S., Jung C. W., Im Y. H., Lee M. H., Park K., Park C. H., Kang W. K., Postoperative chemoradiotherapy for gastric cancer. Annals of Oncology 2003 14 9 1373 1377 2-s2.0-0141613783 10.1093/annonc/mdg366 (Pubitemid 37185282)
9. Jadad A. R., Moore R. A., Carroll D., Jenkinson C., Reynolds D. J. M., Gavaghan D. J., McQuay H. J., Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled Clinical Trials 1996 17 1 1 12 2-s2.0-0029914622 10.1016/0197-2456(95)00134-4 (Pubitemid 26120810)
10. Tierney J. F., Stewart L. A., Ghersi D., Burdett S., Sydes M. R., Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007 7 8 2-s2.0-34547450763 10.1186/1745-6215-8-16 (Pubitemid 47161711)
11. Bucher H. C., Guyatt G. H., Griffith L. E., Walter S. D., The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. Journal of Clinical Epidemiology 1997 50 6 683 691 2-s2.0-0030793120 10.1016/S0895-4356(97)00049-8 (Pubitemid 27341818)
12. Lee J., Lim D. H., Kim S., Park S. H., Park J. O., Park Y. S., Lim H. Y., Choi M. G., Sohn T. S., Noh J. H., Bae J. M., Ahn Y. C., Sohn I., Jung S. H., Park C. K., Kim K.-M., Kang W. K., Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. Journal of Clinical Oncology 2012 30 3 268 273 2-s2.0-84856067529 10.1200/JCO.2011.39.1953
13. Zhu W. G., Xua D. F., Pu J., A randomized, controlled, multicenter study comparing intensity-modulated radiotherapy plus concurrent chemotherapy with chemotherapy alone in gastric cancer patients with D2 resection. Radiotherapy and Oncology 2012 104 3 361 366 10.1016/j.radonc.2012.08.024
14. Kim T. H., Park S. R., Ryu K. W., Phase 3 trial of postoperative chemotherapy alone versus chemoradiation therapy in stage III-IV gastric cancer treated with Ro gastrectomy and D2 lymph node dissection. International Journal of Radiation Oncology 2012 84 5 e585 e592 10.1016/j.ijrobp.2012.07.2378
15. Cirera L., Balil A., Batiste-Alentorn E., Tusquets I., Cardona T., Arcusa À., Jolis L., Saigí E., Guasch I., Badia A., Boleda M., Randomized clinical trial of adjuvant mitomycin plus tegafur in patients with resected stage III gastric cancer. Journal of Clinical Oncology 1999 17 12 3810 3815 2-s2.0-0032798967
16. Nakajima T., Kinoshita T., Nashimoto A., Sairenji M., Yamaguchi T., Sakamoto J., Fujiya T., Inada T., Sasako M., Ohashi Y., Randomized controlled trial of adjuvant uracil-tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer. British Journal of Surgery 2007 94 12 1468 1476 2-s2.0-37249028822 10.1002/bjs.5996 (Pubitemid 350275624)
17. Sasako M., Sakuramoto S., Katai H., Kinoshita T., Furukawa H., Yamaguchi T., Nashimoto A., Fujii M., Nakajima T., Ohashi Y., Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. Journal of Clinical Oncology 2011 29 33 4387 4393 2-s2.0-81755171104 10.1200/JCO.2011.36.5908
18. Bang Y. J., Kim Y. W., Yang H. K., Chung H. C., Park Y. K., Lee K. H., Lee K. W., Kim Y. H., Noh S. I., Cho J. Y., Mok Y. J., Kim Y. H., Ji J., Yeh T. S., Button P., Sirzén F., Noh S. H., Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. The Lancet 2012 379 9813 315 321 2-s2.0-84856382467 10.1016/S0140-6736(11)61873-4
19. Song F., Altman D. G., Glenny A. M., Deeks J. J., Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. British Medical Journal 2003 326 7387 472 475 2-s2.0-0037374008 (Pubitemid 36269627)
20. Huang Y. Y., Yang Q., Zhou S. W., Postoperative chemoradiotherapy versus postoperative chemotherapy for completely resected gastric cancer with D2 lymphadenectomy: a meta-analysis. PLoS ONE 2013 8 7 e68939
21. Landry J., Tepper J. E., Wood W. C., Moulton E. O., Koerner F., Sullinger J., Patterns of failure following curative resection of gastric carcinoma. International Journal of Radiation Oncology Biology Physics 1990 19 6 1357 1362 2-s2.0-0025668078
22. Hsu C., Shen Y. C., Cheng C. C., Cheng A. L., Hu F. C., Yeh K. H., Geographic difference in safety and efficacy of systemic chemotherapy for advanced gastric or gastroesophageal carcinoma: a meta-analysis and meta-regression. Gastric Cancer 2012 1 16 2-s2.0-84856574419 10.1007/s10120-011-0106-5
23. Brooks G. A., Enzinger P. C., Fuchs C. S., Adjuvant therapy for gastric cancer: revisiting the past to clarify the future. Journal of Clinical Oncology 2012 30 19 2297 2299
24. Zárate R. N. R., Arias F., Bandres E., Cubedo E., Malumbres R., García-Foncillas J., Xeroderma pigmentosum group D 751 polymorphism as a predictive factor in resected gastric cancer treated with chemo-radiotherapy. World Journal of Gastroenterology 2006 12 37 6032 6036 2-s2.0-33750257521 (Pubitemid 44608484)
25. Gordon M. A., Gundacker H. M., Benedetti J., Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Annals of Oncology 2013 24 7 1754 1761